Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

KLRS has been the subject of several other reports. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Chardan Capital began coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price target on the stock. Finally, Citizens Jmp assumed coverage on shares of Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Kalaris Therapeutics Price Performance

NASDAQ:KLRS opened at $10.00 on Friday. The firm has a market capitalization of $187 million, a price-to-earnings ratio of -2.65 and a beta of -0.09. The business has a 50 day simple moving average of $9.22 and a 200-day simple moving average of $6.38. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $12.90.

Insider Buying and Selling

In related news, Director Srinivas Akkaraju purchased 479,847 shares of Kalaris Therapeutics stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average price of $10.42 per share, with a total value of $5,000,005.74. Following the purchase, the director directly owned 1,979,847 shares of the company’s stock, valued at approximately $20,630,005.74. This represents a 31.99% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 74.99% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kalaris Therapeutics

Several large investors have recently added to or reduced their stakes in KLRS. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kalaris Therapeutics during the fourth quarter worth approximately $34,000. Barclays PLC purchased a new stake in shares of Kalaris Therapeutics in the fourth quarter valued at approximately $51,000. Johnson Financial Group Inc. bought a new position in Kalaris Therapeutics in the third quarter worth approximately $58,000. XTX Topco Ltd purchased a new position in Kalaris Therapeutics during the 2nd quarter worth $65,000. Finally, Keel Point LLC bought a new stake in Kalaris Therapeutics during the 4th quarter valued at $86,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.